0001062822-26-000101
SEC filingLexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, up 1572.1% year-over-year, driven by strong product sales and milestones, while narrowing operating and net losses significantly through cost discipline.
Lexicon Pharmaceuticals delivered transformative Q1 2026 financial results, propelled by a revenue surge to $21.1 million from $1.3 million in the prior year, representing 1572.1% growth. This leap stems from INPEFA product sales leveraging zero-cost inventory obtained in conjunction with a terminated 2019 agreement or previously expensed as research and development. Consequently, gross profit reached $21.0 million, yielding an exceptional 99.5% gross margin as minimal cost of sales was recognized against this inventory base.
Despite the revenue momentum, operating income reflected a modest loss of $996 thousand, a 96.1% improvement from the $25.7 million deficit last year. This narrowing occurred because operating expenses, while substantial, did not fully offset the revenue influx but were contained relative to the scaled-up top line. Net income followed suit at a $1.0 million loss, 95.9% better than prior year, with diluted EPS breakeven at $0.00 compared to -$0.07. These outcomes underscore effective cost discipline amid a transition to revenue-generating operations.